Leteprinim
 | |
| Clinical data | |
|---|---|
| ATC code | none |
| Identifiers | |
| |
| CAS Number |
138117-50-7  |
| PubChem (CID) | 132123 |
| ChemSpider | 116710 |
| UNII |
NBY3IU407M |
| Chemical and physical data | |
| Formula | C15H13N5O4 |
| Molar mass | 327.295 |
| 3D model (Jmol) | Interactive image |
| |
| |
| (verify) | |
Leteprinim (Neotrofin, AIT-082) is a hypoxanthine derivative drug with neuroprotective and nootropic effects.[1][2][3] It stimulates release of nerve growth factors and enhances survival of neurons in the brain,[4][5][6][7][8] and is under development as a potential treatment for neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and stroke.[9][10]
References
- ↑ Di Iorio, P; Virgilio, A; Giuliani, P; Ballerini, P; Vianale, G; Middlemiss, P. J.; Rathbone, M. P.; Ciccarelli, R (2001). "AIT-082 is neuroprotective against kainate-induced neuronal injury in rats". Experimental Neurology. 169 (2): 392–9. doi:10.1006/exnr.2001.7654. PMID 11358452.
- ↑ Lahiri, D. K.; Ge, Y. W.; Farlow, M. R. (2000). "Effect of a memory-enhancing drug, AIT-082, on the level of synaptophysin". Annals of the New York Academy of Sciences. 903: 387–93. PMID 10818529.
- ↑ Yan, R; Nguyen, Q; Gonzaga, J; Johnson, M; Ritzmann, R. F.; Taylor, E. M. (2003). "Reversal of cycloheximide-induced memory disruption by AIT-082 (Neotrofin) is modulated by, but not dependent on, adrenal hormones". Psychopharmacology. 166 (4): 400–7. doi:10.1007/s00213-002-1350-5 (inactive 2016-08-15). PMID 12605287.
- ↑ Rathbone, M. P.; Middlemiss, P. J.; Crocker, C. E.; Glasky, M. S.; Juurlink, B. H.; Ramirez, J. J.; Ciccarelli, R; Di Iorio, P; Caciagli, F (1999). "AIT-082 as a potential neuroprotective and regenerative agent in stroke and central nervous system injury". Expert Opinion on Investigational Drugs. 8 (8): 1255–62. doi:10.1517/13543784.8.8.1255. PMID 15992149.
- ↑ Ramirez, J. J.; Parakh, T; George, M. N.; Freeman, L; Thomas, A. A.; White, C. C.; Becton, A (2002). "The effects of Neotrofin on septodentate sprouting after unilateral entorhinal cortex lesions in rats". Restorative neurology and neuroscience. 20 (1–2): 51–9. PMID 12237496.
- ↑ Holmes, M; Maysinger, D; Foerster, A; Pertens, E; Barlas, C; Diamond, J (2003). "Neotrofin, a novel purine that induces NGF-dependent nociceptive nerve sprouting but not hyperalgesia in adult rat skin". Molecular and cellular neurosciences. 24 (3): 568–80. PMID 14664808.
- ↑ Jiang, S; Khan, M. I.; Middlemiss, P. J.; Lu, Y; Werstiuk, E. S.; Crocker, C. E.; Ciccarelli, R; Caciagli, F; Rathbone, M. P. (2004). "AIT-082 and methylprednisolone singly, but not in combination, enhance functional and histological improvement after acute spinal cord injury in rats". International journal of immunopathology and pharmacology. 17 (3): 353–66. PMID 15461869.
- ↑ Calcutt, N. A.; Freshwater, J. D.; Hauptmann, N; Taylor, E. M.; Mizisin, A. P. (2006). "Protection of sensory function in diabetic rats by Neotrofin". European Journal of Pharmacology. 534 (1–3): 187–93. doi:10.1016/j.ejphar.2006.01.047. PMID 16507305.
- ↑ Potkin, S. G.; Alva, G; Keator, D; Carreon, D; Fleming, K; Fallon, J. H. (2002). "Brain metabolic effects of Neotrofin in patients with Alzheimer's disease". Brain research. 951 (1): 87–95. PMID 12231461.
- ↑ Johnston, T. H.; Brotchie, J. M. (2004). "Drugs in development for Parkinson's disease". Current opinion in investigational drugs (London, England : 2000). 5 (7): 720–6. PMID 15298067.
This article is issued from Wikipedia - version of the 8/15/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.